rs967317406
Variant summary
Our verdict is Uncertain significance. The variant received -1 ACMG points: 0P and 1B. BP4
This summary comes from the ClinGen Evidence Repository: NM_001754.5(RUNX1):c.1266G>C (p.Glu422Asp) is a missense variant which has a REVEL score < 0.50 (0.11) and a SpliceAI score ≤ 0.20 (0.0) (BP4). In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BP4. LINK:https://erepo.genome.network/evrepo/ui/classification/CA16616259/MONDO:0011071/008
Frequency
Consequence
NM_001754.5 missense
Scores
Clinical Significance
Conservation
Publications
- hereditary thrombocytopenia and hematologic cancer predisposition syndromeInheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: ClinGen, Orphanet
- hereditary thrombocytopenia and hematological cancer predisposition syndrome associated with RUNX1Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Ambry Genetics, Genomics England PanelApp, G2P, Labcorp Genetics (formerly Invitae)
- acute myeloid leukemiaInheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
Genome browser will be placed here
ACMG classification
Our verdict: Uncertain_significance. The variant received -1 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.00000663 AC: 1AN: 150848Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.0000139 AC: 2AN: 144372 AF XY: 0.0000129 show subpopulations
GnomAD4 exome AF: 0.0000202 AC: 28AN: 1388352Hom.: 0 Cov.: 37 AF XY: 0.0000190 AC XY: 13AN XY: 685768 show subpopulations ⚠️ The allele balance in gnomAD version 4 Exomes is significantly skewed from the expected value of 0.5.
Age Distribution
GnomAD4 genome AF: 0.00000663 AC: 1AN: 150848Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 73642 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
Inborn genetic diseases Uncertain:1
The p.E422D variant (also known as c.1266G>C), located in coding exon 8 of the RUNX1 gene, results from a G to C substitution at nucleotide position 1266. The glutamic acid at codon 422 is replaced by aspartic acid, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. -
Hereditary thrombocytopenia and hematologic cancer predisposition syndrome Uncertain:1
NM_001754.5(RUNX1):c.1266G>C (p.Glu422Asp) is a missense variant which has a REVEL score < 0.50 (0.11) and a SpliceAI score ≤ 0.20 (0.0) (BP4). In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BP4. -
Hereditary thrombocytopenia and hematological cancer predisposition syndrome associated with RUNX1 Uncertain:1
This sequence change replaces glutamic acid, which is acidic and polar, with aspartic acid, which is acidic and polar, at codon 422 of the RUNX1 protein (p.Glu422Asp). This variant is present in population databases (no rsID available, gnomAD 0.004%). This variant has not been reported in the literature in individuals affected with RUNX1-related conditions. ClinVar contains an entry for this variant (Variation ID: 409823). An algorithm developed to predict the effect of missense changes on protein structure and function outputs the following: PolyPhen-2: "Benign". The aspartic acid amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Acute myeloid leukemia Uncertain:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at